Chardan analyst Daniil Gataulin initiated coverage of Tourmaline Bio (TRML) with a Buy rating and $70 price target The firm cites the potential of the company’s lead asset, the anti-IL6 antibody pacibekitug, in thyroid eye disease and atherosclerotic cardiovascular disease for the Buy rating. It also sees additional upside potential in abdominal aortic aneurysm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio’s Strategic Advancements and Financial Strength Drive Buy Rating
- Tourmaline Bio price target lowered to $63 from $74 at Truist
- Truist biotech analyst holds an analyst/industry conference call
- Tourmaline Bio’s TOUR006: Potential Best-in-Class IL-6 Treatment with Strategic Market Positioning
- Positive Buy Rating for Tourmaline Bio Driven by Promising Pacibekitug Developments and Strategic Value